Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Non-Segmental Vitiligo

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Mar 2024 Results of exploratory analysis (n=139) assessing patient-assessed level of bother from vitiligo on the face and genitals among patients receiving upadacitinib presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Results (n=115) assessing Psychometric Properties of the Vitiligo Noticeability Scale (VNS) Using Data From this study presented at the American Academy of Dermatology annual Meeting 2024
12 Mar 2024 Results (n=164) assessing the psychometric characteristics of F-VASI and T-VASI presented at the American Academy of Dermatology annual Meeting 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com